Abstracts tagged "B cells"

Abstract Number: 1748 • 2017 ACR/ARHP Annual Meeting
Cbl-b Associates with Bcl-6 and Is Differentially Expressed in Circulating Follicular T Helper Cells of Patients with Systemic Lupus Erythematosus
Jeffrey Hampton¹, Giancarlo R. Valiente², Armin Munir³, Takuma Tsuzuki Wada³, William Willis³, Nicholas A. Young³, Lai-Chu Wu⁴, Jian Zhang⁵ and Wael Jarjour³, ¹Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ²Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Activation of polyclonal CD4+ T cells and B cells is a hallmark of human and murine lupus, which suggests a global defect in the…
Abstract Number: 42 • 2017 ACR/ARHP Annual Meeting
Resveratrol Regulates Sirt1 to Control B Cells Activation and Plasma B Cells Differentiation
Ting Wang¹, Xing Song², Xiaofang Luo², Mengtao Li² and Xiaofeng Zeng¹, ¹Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease characterized by B cell hyperactivation and the production of autoantibodies. Histone deacetylase, Sirtuin1 (Sirt1) has…
Abstract Number: 1782 • 2017 ACR/ARHP Annual Meeting
Mycophenolic Acid Decreases IL-10 and IL-6 Production By B Cells of Granulomatosis with Polyangiitis Patients and Healthy Controls in Vitro
Anouk von Borstel¹, Wayel H. Abdulahad², Abraham Rutgers², Judith Land², Coen A. Stegeman¹, Peter Heeringa³ and Jan-Stephan F. Sanders¹, ¹Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a relapsing autoimmune disease affecting small- to medium-sized blood vessels. B cells are thought to play an important antibody-independent…
Abstract Number: 43 • 2017 ACR/ARHP Annual Meeting
Regulation of TLR7 Signalling By UBE2L3 Dependent Linear Ubiquitination Explains Dimethyl Fumarate Suppression of Autoreactive B Cell Development in SLE
Daniele Mauro¹, Victoria Tsang², Isabelle A. Clayton-Lucey³, Sara Pagani², Farah Alam², Elena Pontarini², Alessandra Nerviani², Angela Pakozdi⁴, Andrea Cove-Smith⁴, Ravindra Rajakariar⁴, Debasish Pyne⁴, Timothy J Vyse⁵, Costantino Pitzalis² and Myles J. Lewis^4,6, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ²Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ³Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary University of London, EC1M 6BQ, United Kingdom, ⁴Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom, ⁵Division of Genetics and Molecular Medicine, King's College London, Guy's Hospital, London, United Kingdom, ⁶Rheumatology, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: A single risk haplotype spanning UBE2L3 is strongly associated with SLE and multiple autoimmune diseases. The E2 ubiquitin-conjugating enzyme UBE2L3 regulates TNFα and CD40…
Abstract Number: 1834 • 2017 ACR/ARHP Annual Meeting
Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells
Javier Rangel-Moreno¹, Jennifer Barnard², Shelton Cochran³, Margaret Lee³, Sharon Tamir³ and Jennifer H. Anolik⁴, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: There is great interest in developing new treatment approaches for systemic lupus erythematosus (SLE), but the biologic therapies under investigation over the past several…
Abstract Number: 104 • 2017 Pediatric Rheumatology Symposium
Rituximab Treatment for Chronic Steroid-Dependent Henoch-Schonlein Purpura
Esraa M. A. Eloseily^1,2, Courtney Crayne¹, Melissa L Mannion³, Saji P Azerf⁴, Peter Weiser¹, Timothy Beukelman¹, Matthew L. Stoll¹, Dan Feig⁵, Prescott Atkinson⁶ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of medicine, Univesity of Alabama at Birmingham,, Birmingham, AL, ⁵Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Henoch-Schonlein purpura (HSP) is a small vessel vasculitis characterized by non-thrombocytopenic purpura, abdominal pain, arthritis, and glomerulonephritis. Typically, HSP is self-limited, but more severe…
Abstract Number: 19 • 2017 Pediatric Rheumatology Symposium
The Lymphocyte Repertoire in Juvenile Dermatomyositis
Kacie Hoyt¹, Edwin Anderson^1,2, Megan L. Curran³, Robert Fuhlbrigge⁴, Luigi Notarangelo⁵, Lauren M. Pachman⁶, Susan Kim⁷ and Lauren Henderson⁸, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Clinical Research Center/Rheumatology, Boston Children's Hospital, Medford, MA, ³Pediatric Rheumatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Children's Hospital Colorado, Aurora, CO, ⁵National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁶Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁷Pediatric Rheumatology, University of California, San francisco School of Medicine, San Francisco, CA, ⁸Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: In adult dermatomyositis (DM), clonal populations of T and B cells with shared variable (V) gene usage have been identified in affected muscle, suggesting…
Abstract Number: 7 • 2017 Pediatric Rheumatology Symposium
Activation of Immature, Transitional B cells by Integrated BCR, TLR and TACI signals promotes systemic autoimmunity in high BAFF settings
Holly Jacobs, Samuel Du, Tanvi Arkatkar and Shaun Jackson, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: B cell activating factor of the TNF family (BAFF, also known as BLyS) promotes B cell survival and activation by binding distinct B cell…
Abstract Number: 781 • 2016 ACR/ARHP Annual Meeting
The Use of Rituximab in Newly Diagnosed Systemic Lupus Erythematosus Patients: Long Term Steroid Saving Capacity and Clinical Effectiveness
Borja del Carmelo Gracia Tello Sr.¹, David A. Isenberg² and Amara Ezeonyeji³, ¹Internal Medicina, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, University College of London Hospital, London, London, United Kingdom
Background/Purpose: To assess the long term steroid saving capacity and clinical effectiveness of B-cell depletion therapy (BCDT) in newly diagnosed SLE patients. Methods: Sixteen female…
Abstract Number: 1610 • 2016 ACR/ARHP Annual Meeting
Safety, Tolerability, and Dose-Dependent Inhibition of T-Cell-Dependent Antibody Response with MEDI4920, a Novel, Engineered CD40L Antagonist: Results of a Single-Ascending Dose Study in Healthy Volunteers
Marius Albulescu¹, Jim Bush², Firas Almazedi², Ethan Grant³, Alex Godwood¹, Robert Miday⁴, Krista Arbaugh⁴, Lisa H. Butler¹, Michele Gunsior⁴, Jing Li⁵ and David Howe¹, ¹MedImmune, Cambridge, United Kingdom, ²Covance Clinical Research Unit, Leeds, United Kingdom, ³Translational Medicine, MedImmune, Gaithersburg, MD, ⁴MedImmune, Gaithersburg, MD, ⁵MedImmune, Mountain View, CA
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production. Previous clinical programs with intact monoclonal antibodies against CD40L have been discontinued due to…
Abstract Number: 2608 • 2016 ACR/ARHP Annual Meeting
Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab
Atsushi Noguchi^1,2, Shinsuke Yasuda¹, Ryo Hisada¹, Kazumasa Ohmura¹, Sanae Shimamura¹, Yuka Shimizu¹, Masaru Kato¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Miho Suzuki³, Yoshihiro Matsumoto⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Product research department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ⁴Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Consecutive RA patients who initiated treatment with TCZ between December 2013 and September 2015 were enrolled in our prospective study. All patients met 2010…
Abstract Number: 783 • 2016 ACR/ARHP Annual Meeting
Review of SLE Cohort to Identify Predictors of Response to B Cell Depletion in Patients with Active SLE
Pedro Mota¹, Ashleigh Hennessey², Ada Ferenkeh-Koroma² and David A. Isenberg², ¹Internal Medicine, Hospital da Luz, Lisbon, Portugal, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: The use of Rituximab (RTX) has been documented via published cohort data from over 20 sites worldwide (1,2) demonstrating its useful role in the…
Abstract Number: 1650 • 2016 ACR/ARHP Annual Meeting
Treatment with Tofacitinib Inhibits Human Naive B Lymphocyte Development and Function in Vitro
Jens Thiel¹, Nils Venhoff², Raquel Lorenzetti³, Bettina Bannert¹, Reinhard Voll⁴, Diego Kyburz⁵ and Marta Rizzi¹, ¹Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, Freiburg, Germany, ²Department of Internal Medicine, Clinic for Rheumatology and Clincal Immunology, Freiburg, Germany, ³Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, 79106, Germany, ⁴Dpt. Rheumatology & Clinical Immunology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, University Medical Center, University of Freiburg, Freiburg, Germany, ⁵Department of Biomedicine, Experimental Rheumatology, University of Basel, 4051 Basel, Switzerland
Background/Purpose: B cells are pivotal to the pathogenesis of many autoimmune diseases including rheumatoid arthritis (RA). Tofacitinib, a JAK inhibitor, is effective and safe in…
Abstract Number: 2701 • 2016 ACR/ARHP Annual Meeting
Increased Frequency of Regulatory CD19+CD24high Cd38high B Cells in Patients with Ankylosing Spondylitis (AS)
M. Belén Bautista-Caro¹, Eugenio De Miguel¹, Diana Peiteado¹, Chamaida Plasencia-Rodriguez¹, Alejandro Villalba¹, Amaya Puig-Kröger², Paloma Sanchez-Mateos³, Emilio Martín-Mola¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain, ³Immunology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: CD19+CD24highCD38high B cells have been described to have a regulatory capacity and their frequency is altered in the peripheral blood of patients with various…
Abstract Number: 811 • 2016 ACR/ARHP Annual Meeting
Basophils Are Activated and Stimulate Both B Cells and Fibroblasts in Systemic Sclerosis
Benjamin Chaigne¹, Nicolas Dumoitier², Alexis Regent¹, Benjamin Terrier³, Jonathan London², Matthieu Groh¹, Nathalie Thieblemont⁴ and Luc Mouthon⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ³Internal Medicine, Cochin Hospital, Paris, France, ⁴Inserm U1016, Paris, France, ⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem connective tissue disease characterized by skin and internal organs fibrosis and vascular abnormalities, along with the presence…

« Previous Page
1
…
6
7
8
9
10
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].